vTv Therapeutics Inc logo

vTv Therapeutics Inc

$ 0.97 +0.0416 (+4.49%) 08:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 78.92M
Enterprise V:
$ 58.26M
Volume:
62.04K
Avg Vol (2M):
216.23K
Also Trade In:
Volume:
62.04K
Market Cap $:
78.92M
PE Ratio:
At Loss
Avg Vol (2-Month):
216.23K
Enterprise Value $:
58.26M
PB Ratio:
0
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Name Current Vs Industry Vs History
Cash-To-Debt 30.43
Equity-to-Asset -0.23
Debt-to-Equity -0.07
Debt-to-EBITDA -0.02
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.94
Distress
Grey
Safe
Beneish M-Score -4.29
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 34.8
9-Day RSI 35.3
14-Day RSI 39.45
6-1 Month Momentum % 59.69
12-1 Month Momentum % -27.56

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.12
Quick Ratio 3.12
Cash Ratio 1.82
Days Sales Outstanding 20.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -48.7
Name Current Vs Industry Vs History
Operating Margin % -462.73
Net Margin % -364.61
ROA % -67.39
ROIC % -232.49
ROC (Joel Greenblatt) % -3538.98
ROCE % -128.25

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 12.87
EV-to-EBIT -2.71
EV-to-EBITDA -2.72
EV-to-Revenue 13.07
EV-to-Forward-Revenue 29.13
EV-to-FCF -5.64
Earnings Yield (Greenblatt) % -36.88

Financials (Next Earnings Date:2022-11-09 Est.)

VTVT's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VTVT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 5.018
EPS (TTM) ($) -0.27
Beta 0.4
Volatility % 69.37
14-Day RSI 39.45
14-Day ATR ($) 0.090634
20-Day SMA ($) 1.038215
12-1 Month Momentum % -27.56
52-Week Range ($) 0.382 - 1.76
Shares Outstanding (Mil) 81.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

vTv Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

vTv Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.